Belpointe Asset Management LLC Purchases New Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Posted by Defense World Staff on May 15th, 2023

Belpointe Asset Management LLC acquired a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 29,900 shares of the biotechnology company’s stock, valued at approximately $360,000. Belpointe Asset Management LLC owned about 0.08% of Oramed Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Point72 Hong Kong Ltd lifted its stake in Oramed Pharmaceuticals by 113.5% in the first quarter. Point72 Hong Kong Ltd now owns 4,552 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 2,420 shares during the period. UBS Group AG raised its stake in Oramed Pharmaceuticals by 84.9% in the third quarter. UBS Group AG now owns 8,415 shares of the biotechnology company’s stock worth $54,000 after buying an additional 3,864 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in Oramed Pharmaceuticals by 26.8% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 14,184 shares of the biotechnology company’s stock worth $92,000 after buying an additional 3,000 shares in the last quarter. Glass Jacobson Investment Advisors llc purchased a new stake in Oramed Pharmaceuticals during the fourth quarter worth $112,000. Finally, Barclays PLC boosted its position in Oramed Pharmaceuticals by 8.7% during the 3rd quarter. Barclays PLC now owns 21,543 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 1,724 shares in the last quarter. Institutional investors own 10.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ORMP shares. HC Wainwright cut Oramed Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 17th. StockNews.com raised shares of Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 18th.

Insider Buying and Selling at Oramed Pharmaceuticals

In other news, Director Yadin Rozov acquired 20,000 shares of Oramed Pharmaceuticals stock in a transaction dated Monday, March 13th. The stock was purchased at an average cost of $1.96 per share, for a total transaction of $39,200.00. Following the completion of the purchase, the director now directly owns 36,500 shares in the company, valued at approximately $71,540. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Yadin Rozov purchased 20,000 shares of Oramed Pharmaceuticals stock in a transaction that occurred on Monday, March 13th. The stock was bought at an average cost of $1.96 per share, for a total transaction of $39,200.00. Following the completion of the transaction, the director now owns 36,500 shares in the company, valued at $71,540. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Nadav Kidron purchased 26,000 shares of the stock in a transaction that occurred on Thursday, March 16th. The shares were purchased at an average cost of $2.04 per share, for a total transaction of $53,040.00. Following the completion of the acquisition, the chief executive officer now directly owns 126,000 shares of the company’s stock, valued at approximately $257,040. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 146,000 shares of company stock worth $293,240. 6.90% of the stock is currently owned by insiders.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ:ORMP opened at $2.83 on Monday. Oramed Pharmaceuticals Inc. has a 1 year low of $1.81 and a 1 year high of $13.73. The firm has a market capitalization of $112.59 million, a P/E ratio of -3.01 and a beta of 1.81. The business’s 50-day moving average is $2.30 and its 200 day moving average is $4.77.

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) last posted its quarterly earnings data on Monday, March 6th. The biotechnology company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). Oramed Pharmaceuticals had a negative net margin of 1,353.35% and a negative return on equity of 23.62%. The business had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.75 million. On average, analysts expect that Oramed Pharmaceuticals Inc. will post -0.77 EPS for the current year.

Oramed Pharmaceuticals Profile

(Get Rating)

Oramed Pharmaceuticals, Inc engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.